文献速递系统性红斑狼疮

不列颠群岛狼疮评估组生物制剂登记(BILAG-BR)中接受利妥昔单抗或贝利尤单抗治疗的系统性红斑狼疮患者早期感染风险:一项前瞻性纵向研究

Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study.
PubMed 文献 · Lancet Rheumatol · 2023-01-01

基于英国64中心前瞻性BILAG-BR登记,2010年7月1日至2021年2月23日纳入1048例中重度SLE患者,比较利妥昔单抗、贝利尤单抗与标准治疗12个月内严重感染风险。三组严重感染风险相似,多病共存、低丙种球蛋白血症和泼尼松龙剂量>10 mg与严重感染风险相关。

要点

  • 利妥昔单抗组与贝利尤单抗组严重感染风险与标准治疗组相似。
  • 泼尼松龙剂量>10 mg、低丙种球蛋白血症和多病共存与严重感染风险相关。
  • 研究期间发生6例感染相关死亡,中位时间为入组后121天。

核心结论

  • 在中重度SLE患者中,利妥昔单抗、贝利尤单抗和标准免疫抑制治疗的严重感染风险相似。
  • 严重感染的关键危险因素包括多病共存、低丙种球蛋白血症和糖皮质激素剂量增加。
  • 作者提出,在考虑严重感染风险时,应将免疫抑制剂、利妥昔单抗和贝利尤单抗优先作为主要治疗,以优化SLE管理并支持主动减少糖皮质激素使用。

研究设计与样本

  • BILAG-BR为英国前瞻性登记,由治疗医生在常规诊疗中招募患者,覆盖英国64个中心,使用标准化病例报告表。
  • 纳入标准包括年龄大于5岁、能提供知情同意、诊断为SLE,并在过去12个月内开始新的生物制剂治疗或过去1个月内开始新的标准治疗药物。
  • 主要结局为治疗开始后12个月内严重感染的发生率,严重感染定义为需要静脉抗生素治疗、住院或导致病残或死亡。
  • 感染和死亡数据来自研究中心,额外死亡数据来自英国国家统计局。
  • 采用多失败Cox比例风险模型分析严重感染与药物类型的关系。

主要发现

  • 2010年7月1日至2021年2月23日共招募1383人,排除335人后,1048名参与者贡献1002.7人年随访,其中利妥昔单抗746人(71%)、贝利尤单抗119人(11%)、标准治疗183人(17%)。
  • 队列中位年龄39岁(IQR 30-50),女性942/1048(90%),男性106/1048(10%);有族裔数据的911人中,白人514人(56%)、亚裔169人(19%)、黑人161人(18%)、多混血或其他族裔67人(7%)。
  • 12个月研究期间,76人发生118例严重感染,其中利妥昔单抗组58人发生92例、贝利尤单抗组5人发生8例、标准治疗组13人发生18例。
  • 严重感染总体粗发生率为117.7/1000人年(95%CI 98.3-141.0)。
  • 与标准治疗相比,利妥昔单抗组严重感染风险相似(校正HR 1.68[0.60-4.68]),贝利尤单抗组亦相似(1.01[0.21-4.80])。

关键数值与推荐

  • 全队列多变量分析中,严重感染风险与泼尼松龙剂量>10 mg相关(HR 2.38[95%CI 1.47-3.84])。
  • 严重感染风险与低丙种球蛋白血症(<6 g/L)相关(HR 2.16[1.38-3.37])。
  • 严重感染风险与多病共存相关(HR 1.45[1.17-1.80])。
  • 额外的联合免疫抑制使用似乎与风险降低相关(HR 0.60[0.41-0.90])。
  • 未发现非典型感染方面的显著安全信号;发生6例感染相关死亡,中位时间为入组后121天(IQR 60-151)。

临床怎么用

  • 作者提出,在考虑严重感染风险时,应将免疫抑制剂、利妥昔单抗和贝利尤单抗优先作为主要治疗,以优化SLE管理并支持主动减少糖皮质激素使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with systemic lupus erythematosus (SLE) are at an increased risk of infection relative to the general population. We aimed to describe the frequency and risk factors for serious infections in patients with moderate-to-severe SLE treated with rituximab, belimumab, and standard of care therapies in a large national observational cohort. METHODS: The British Isles Lupus Assessment Group Biologics Register (BILAG-BR) is a UK-based prospective register of patients with SLE. Patients were recruited by their treating physician as part of their scheduled care from 64 centres across the UK by use of a standardised case report form. Inclusion criteria for the BILAG-BR included age older than 5 years, ability to provide informed consent, a diagnosis of SLE, and starting a new biological therapy within the last 12 months or a new standard of care drug within the last month. The primary outcome for this study was the rate of serious infections within the first 12 months of therapy. Serious infections were defined as those requiring intravenous antibiotic treatment, hospital admission, or resulting in morbidity or death. Infection and mortality data were collected from study centres and further mortality data were collected from the UK Office for National Statistics. The relationship between serious infection and drug type was analysed using a multiple-failure Cox proportional hazards model. FINDINGS: Between July 1, 2010, and Feb 23, 2021, 1383 individuals were recruited to the BILAG-BR. 335 patients were excluded from this analysis. The remaining 1048 participants contributed 1002·7 person-years of follow-up and included 746 (71%) participants on rituximab, 119 (11%) participants on belimumab, and 183 (17%) participants on standard of care. The median age of the cohort was 39 years (IQR 30-50), 942 (90%) of 1048 patients were women and 106 (10%) were men. Of the patients with available ethnicity data, 514 (56%) of 911 were White, 169 (19%) were Asian, 161 (18%) were Black, and 67 (7%) were of multiple-mixed or other ethnic backgrounds. 118 serious infections occurred in 76 individuals during the 12-month study period, which included 92 serious infections in 58 individuals on rituximab, eight serious infections in five individuals receiving belimumab, and 18 serious infections in 13 individuals on standard of care. The overall crude incidence rate of serious infection was 117·7 (95% CI 98·3-141·0) per 1000 person-years. Compared with standard of care, the serious infection risk was similar in the rituximab (adjusted hazard ratio [HR] 1·68 [0·60-4·68]) and belimumab groups (1·01 [0·21-4·80]). Across the whole cohort in multivariate analysis, serious infection risk was associated with prednisolone dose (>10 mg; 2·38 [95%CI 1·47-3·84]), hypogammaglobulinaemia (<6 g/L; 2·16 [1·38-3·37]), and multimorbidity (1·45 [1·17-1·80]). Additional concomitant immunosuppressive use appeared to be associated with a reduced risk (0·60 [0·41-0·90]). We found no significant safety signals regarding atypical infections. Six infection-related deaths occurred at a median of 121 days (IQR 60-151) days from cohort entry. INTERPRETATION: In patients with moderate-to-severe SLE, rituximab, belimumab, and standard immunosuppressive therapy have similar serious infection risks. Key risk factors for serious infections included multimorbidity, hypogammaglobulinaemia, and increased glucocorticoid doses. When considering the risk of serious infection, we propose that immunosupppressives, rituximab, and belimumab should be prioritised as mainstay therapies to optimise SLE management and support proactive minimisation of glucocorticoid use. FUNDING: None.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Rodziewicz M, Dyball S, Lunt M, et al. Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study. Lancet Rheumatol. 2023. PMID: 38251591. doi:10.1016/S2665-9913(23)00091-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。